undamentalytics Newsletter
Sign in

Mesoblast LTD revenue

Mesoblast LTD's revenue was $120m in fiscal 2026, up 599.2% on the year before. Since fiscal 2016 ($42.5m) it has grown at a compound 10.9% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Jun 20162017Jun 20172018Jun 20182019Jun 20192020Jun 20202021Jun 20212022Jun 20222023Jun 20232024Jun 20242025Jun 20252026Jun 2026
Revenue4321717327108617120
Growth on the year before—−94.3%+618.9%−3.6%+92.3%−76.9%+37.4%−26.5%−21.3%+191.4%+599.2%
Gross profit———————8612104
Gross margin———————100.0%100.0%70.2%86.1%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Mesoblast LTD $120m 599.2% —
Arcus Biosciences, Inc. $117m -55.3% -1.1%
ARS Pharmaceuticals, Inc. $117m 4.1% 711.3%
Agenus Inc $133m 30.5% 10.1%
Xencor Inc $105m -28.6% -2.5%
Kymera Therapeutics, Inc. $102m 133.8% 29.7%

Compare with peers

Head to head: MESO vs RCUSMESO vs SPRYAGEN vs MESO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Mesoblast LTD's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Mesoblast LTD.